Laboratory for Molecular Diagnostics
Center for Nephrology and Metabolic Disorders
Moldiag Diseases Genes Support Contact

Oncogene NRAS

The NRAS gene encodes a membrane protein that shuttles proteins from Golgi apparatus to the plasma membrane. Germline mutations cause autosomal dominant Noonan syndrome 6 and somatic mutation are observed in several tumors.


Clinic Method Carrier testing
Turnaround 5 days
Specimen type genomic DNA
Clinic Method Massive parallel sequencing
Turnaround 25 days
Specimen type genomic DNA
Research Method Genomic sequencing of the entire coding region
Turnaround 25 days
Specimen type genomic DNA
Research Method Multiplex Ligation-Dependent Probe Amplification
Turnaround 25 days
Specimen type genomic DNA

Related Diseases:

Follicular thyroid carcinoma
Noonan syndrome 6



Oliveira JB et al. (2007) NRAS mutation causes a human autoimmune lymphoproliferative syndrome.

external link

Rabin M et al. (1984) NRAS transforming gene maps to region p11----p13 on chromosome 1 by in situ hybridization.

external link

Mitchell EL et al. (1995) Determination of the gene order of the three loci CD2, NGFB, and NRAS at human chromosome band 1p13 and refinement of their localisation at the subband level by fluorescence in situ hybridisation.

external link

Bezieau S et al. (2001) High incidence of N and K-Ras activating mutations in multiple myeloma and primary plasma cell leukemia at diagnosis.

external link

Matallanas D et al. (2003) Differences on the inhibitory specificities of H-Ras, K-Ras, and N-Ras (N17) dominant negative mutants are related to their membrane microlocalization.

external link

Vasko V et al. (2003) Specific pattern of RAS oncogene mutations in follicular thyroid tumors.

external link

Rocks O et al. (2005) An acylation cycle regulates localization and activity of palmitoylated Ras isoforms.

external link

Johnson SM et al. (2005) RAS is regulated by the let-7 microRNA family.

external link

Takahashi C et al. (2006) Nras loss induces metastatic conversion of Rb1-deficient neuroendocrine thyroid tumor.

external link

Miller CA et al. (2013) Genomic landscapes and clonality of de novo AML.

external link

Haigis KM et al. (2008) Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon.

external link

Dessars B et al. (2009) Genotypic and gene expression studies in congenital melanocytic nevi: insight into initial steps of melanotumorigenesis.

external link

Niemela JE et al. (2011) Somatic KRAS mutations associated with a human nonmalignant syndrome of autoimmunity and abnormal leukocyte homeostasis.

external link

Nazarian R et al. (2010) Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation.

external link

Hafner C et al. (2012) Keratinocytic epidermal nevi are associated with mosaic RAS mutations.

external link

Kinsler VA et al. (2013) Multiple congenital melanocytic nevi and neurocutaneous melanosis are caused by postzygotic mutations in codon 61 of NRAS.

external link

Lim YH et al. (2014) Multilineage somatic activating mutations in HRAS and NRAS cause mosaic cutaneous and skeletal lesions, elevated FGF23 and hypophosphatemia.

external link

Li Q et al. (2013) Oncogenic Nras has bimodal effects on stem cells that sustainably increase competitiveness.

external link

Taparowsky E et al. (1983) Structure and activation of the human N-ras gene.

external link

et al. (2013) Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia.

external link

Brewin J et al. (2013) Genomic landscapes and clonality of de novo AML.

external link

Nikiforova MN et al. (2003) RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma.

external link

Matsuda K et al. (2007) Spontaneous improvement of hematologic abnormalities in patients having juvenile myelomonocytic leukemia with specific RAS mutations.

external link

De Filippi P et al. (2009) Germ-line mutation of the NRAS gene may be responsible for the development of juvenile myelomonocytic leukaemia.

external link

Cirstea IC et al. (2010) A restricted spectrum of NRAS mutations causes Noonan syndrome.

external link

Dracopoli NC et al. (1990) Mapping the human amylase gene cluster on the proximal short arm of chromosome 1 using a highly informative (CA)n repeat.

external link

Lübbert M et al. (1990) N-ras gene point mutations in childhood acute lymphocytic leukemia correlate with a poor prognosis.

external link

Hall A et al. (1985) Human N-ras: cDNA cloning and gene structure.

external link

Nitta N et al. (1987) Amino-acid substitution at codon 13 of the N-ras oncogene in rectal cancer in a Japanese patient.

external link

Popescu NC et al. (1985) Chromosomal localization of three human ras genes by in situ molecular hybridization.

external link

Povey S et al. (1985) Report of the Committee on the Genetic Constitution of Chromosomes 1 and 2.

external link

Münke M et al. (1984) Comparative analysis of mouse-human hybrids with rearranged chromosomes 1 by in situ hybridization and Southern blotting: high-resolution mapping of NRAS, NGFB, and AMY on human chromosome 1.

external link

Marshall CJ et al. (1982) A transforming gene present in human sarcoma cell lines.

external link

Ryan J et al. (1983) Chromosomal assignment of a family of human oncogenes.

external link

Yuasa Y et al. (1984) Mechanism of activation of an N-ras oncogene of SW-1271 human lung carcinoma cells.

external link

Davis M et al. (1983) Localisation of the human N-ras oncogene to chromosome 1cen - p21 by in situ hybridisation.

external link

Orphanet article

Orphanet ID 221346 external link

NCBI article

NCBI 4893 external link

OMIM.ORG article

Omim 164790 external link

Wikipedia article

Wikipedia EN (Neuroblastoma_RAS_viral_oncogene_homolog) external link
Update: Aug. 14, 2020
Copyright © 2005-2021 by Center for Nephrology and Metabolic Disorders, Dr. Mato Nagel, MD
Albert-Schweitzer-Ring 32, D-02943 Weißwasser, Germany, Tel.: +49-3576-287922, Fax: +49-3576-287944
Sitemap | Webmail | Disclaimer | Privacy Issues | Website Credits